World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
33930
World Ranking
10059
National Ranking
5178

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Oliver W. Press was affiliated with the University of Washington in the United States. Their research primarily focused on Medicine, with notable contributions in Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging, Oncology, Immunology, and Hematology.

The scientist's work encompassed several key topics, including:

  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Monoclonal and Polyclonal Antibodies Research
  • Radiopharmaceutical Chemistry and Applications
  • Immunotherapy and Immune Responses
  • Multiple Myeloma Research and Treatments
  • Hematopoietic Stem Cell Transplantation

Among their recent papers were:

  • 90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma (2020), published in Bone Marrow Transplantation
  • Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma (2020), published in Transplantation and Cellular Therapy
  • Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA (2020), published in Molecular Cancer Therapeutics
  • A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma (2020), published in American Journal of Hematology
  • Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma (2021), published in Blood Advances

Frequent publication venues for Oliver W. Press included:

  • Transplantation and Cellular Therapy
  • Bone Marrow Transplantation
  • Molecular Cancer Therapeutics
  • Journal of Nuclear Medicine
  • American Journal of Hematology

Collaborations were an important aspect of their research career. Frequent co-authors included:

  • Damian J. Green
  • Ajay K. Gopal
  • Brenda M. Sandmaier
  • Darrell R. Fisher
  • John M. Pagel

Oliver W. Press was recognized as a Member of the Association of American Physicians. The scientist's work contributed to a range of studies within hematology, oncology, and immunotherapy fields before their passing.

Best Publications

  • Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

    Brian G. Till;Brian G. Till;Michael C. Jensen;Jinjuan Wang;Eric Y. Chen

  • Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies

    Daming Shan;Jeffrey A. Ledbetter;Oliver W. Press

  • Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

    Oliver W. Press;Janet F. Eary;Frederick R. Appelbaum;Paul J. Martin

  • CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

    Brian G. Till;Brian G. Till;Michael C. Jensen;Michael C. Jensen;Jinjuan Wang;Xiaojun Qian

  • Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas

    M. S. Kaminski;A. D. Zelenetz;O. W. Press;M. Saleh

  • Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas

    OW Press;F Appelbaum;JA Ledbetter;PJ Martin

  • Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.

    Daming Shan;Jeffrey A. Ledbetter;Oliver W. Press

  • Hickman Catheter Infections in Patients With Malignancies

    Oliver W. Press;Paul G. Ramsey;Eric B. Larson;Alexander Fefer

  • Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas

    O.W Press;O.W Press;F Appelbaum;F Appelbaum;P.J Martin;P.J Martin;D.C Matthews;D.C Matthews

  • Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

    Adam M Petrich;Mitul Gandhi;Borko Jovanovic;Jorge J Castillo

  • Radioimmunotherapy of human tumours

    Steven M. Larson;Jorge A. Carrasquillo;Nai Kong V Cheung;Oliver W. Press

  • New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma

    Richard I. Fisher;Michael LeBlanc;Oliver W. Press;David G. Maloney

  • Non-Hodgkin's Lymphomas

    Andrew D. Zelenetz;Ranjana H. Advani;John C. Byrd;Myron S. Czuczman

  • NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

    Zelenetz Ad;Abramson Js;Advani Rh;Andreadis Cb

  • Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.

    O W Press;J F Eary;C C Badger;P J Martin

  • Evaluation and Management of Chylous Ascites

    Oliver W. Press;Nancy Ottman Press;Sheldon D. Kaufman

  • Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.

    Steven Y. Liu;Janet F. Eary;Stephen H. Petersdorf;Paul J. Martin

  • Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome

    Dana C. Matthews;Dana C. Matthews;Frederick R. Appelbaum;Frederick R. Appelbaum;Janet F. Eary;Janet F. Eary;Darrell R. Fisher;Darrell R. Fisher

  • Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911

    Oliver W. Press;Joseph M. Unger;Rita M. Braziel;David G. Maloney

  • A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.

    Oliver W. Press;Janet F. Eary;Ted Gooley;Ajay K. Gopal

Frequent Co-Authors

David G. Maloney
David G. Maloney Fred Hutchinson Cancer Research Center
Ted Gooley
Ted Gooley Fred Hutchinson Cancer Research Center
William I. Bensinger
William I. Bensinger Fred Hutchinson Cancer Research Center
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center
Brenda M. Sandmaier
Brenda M. Sandmaier Fred Hutchinson Cancer Research Center
Rainer Storb
Rainer Storb Fred Hutchinson Cancer Research Center
Irwin D. Bernstein
Irwin D. Bernstein Fred Hutchinson Cancer Research Center
Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
Julie M. Vose
Julie M. Vose University of Nebraska Medical Center
Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond traditional medical school, a variety of related online degrees offer new routes and faster advancement. Many licensed nurses, for example, are looking to complete their Bachelor of Science in Nursing. rn to bsn programs no clinicals are increasingly popular for their flexibility, as they allow working RNs to earn their degree online without additional in-person clinical demands.

If you're aiming for the highest levels of nursing practice, consider advanced pathways such as dnp programs online. These Doctorate of Nursing Practice degrees are designed for quick completion and flexibility. There are also specialized options for those who value efficiency, including dnp programs online that focus on ease of completion for working professionals.

For those just starting out, accelerated programs like 9 month lpn program pathways provide entry into nursing in less than a year. These programs are ideal for individuals eager to join the healthcare workforce quickly, and can later be a stepping stone to advanced degrees.

Best Scientists Citing Oliver W. Press